keyword
https://read.qxmd.com/read/38698811/the-prognostic-and-immunological-role-of-mcm3-in-pan-cancer-and-validation-of-prognosis-in-a-clinical-lower-grade-glioma-cohort
#1
JOURNAL ARTICLE
Qian-Rong Huang, Qian Jiang, Ju-Yuan Tan, Ren-Bao Nong, Jun Yan, Xia-Wei Yang, Li-Gen Mo, Guo-Yuan Ling, Teng Deng, Yi-Zhen Gong
Background: Previous studies have shown that MCM3 plays a key role in initiating DNA replication. However, the mechanism of MCM3 function in most cancers is still unknown. The aim of our study was to explore the expression, prognostic role, and immunological characteristics of MCM3 across cancers. Methods: We explored the expression pattern of MCM3 across cancers. We subsequently explored the prognostic value of MCM3 expression by using univariate Cox regression analysis. Spearman correlation analysis was performed to determine the correlations between MCM3 and immune-related characteristics, mismatching repair (MMR) signatures, RNA modulator genes, cancer stemness, programmed cell death (PCD) gene expression, tumour mutation burden (TMB), microsatellite instability (MSI), and neoantigen levels...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38698238/predictability-of-b-cell-clonal-persistence-and-immunosurveillance-in-breast-cancer
#2
JOURNAL ARTICLE
Stephen-John Sammut, Jacob D Galson, Ralph Minter, Bo Sun, Suet-Feung Chin, Leticia De Mattos-Arruda, Donna K Finch, Sebastian Schätzle, Jorge Dias, Oscar M Rueda, Joan Seoane, Jane Osbourn, Carlos Caldas, Rachael J M Bashford-Rogers
B cells and T cells are important components of the adaptive immune system and mediate anticancer immunity. The T cell landscape in cancer is well characterized, but the contribution of B cells to anticancer immunosurveillance is less well explored. Here we show an integrative analysis of the B cell and T cell receptor repertoire from individuals with metastatic breast cancer and individuals with early breast cancer during neoadjuvant therapy. Using immune receptor, RNA and whole-exome sequencing, we show that both B cell and T cell responses seem to coevolve with the metastatic cancer genomes and mirror tumor mutational and neoantigen architecture...
May 2024: Nature Immunology
https://read.qxmd.com/read/38686582/immunomodulatory-activity-of-cytokines-in-hypertension-a-vascular-perspective
#3
REVIEW
Rinaldo R Dos Passos, Cintia V Santos, Fernanda Priviero, Ana M Briones, Rita C Tostes, R Clinton Webb, Gisele F Bomfim
Cytokines play a crucial role in the structure and function of blood vessels in hypertension. Hypertension damages blood vessels by mechanisms linked to shear forces, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, oxidative stress, and a proinflammatory milieu that lead to the generation of neoantigens and damage-associated molecular patterns, ultimately triggering the release of numerous cytokines. Damage-associated molecular patterns are recognized by PRRs (pattern recognition receptors) and activate inflammatory mechanisms in endothelial cells, smooth muscle cells, perivascular nerves, and perivascular adipose tissue...
April 30, 2024: Hypertension
https://read.qxmd.com/read/38684865/identification-and-affinity-enhancement-of-t-cell-receptor-targeting-a-kras-g12v-cancer-neoantigen
#4
JOURNAL ARTICLE
Mengyu Zhang, Wei Xu, Lingjie Luo, Fenghui Guan, Xiangyao Wang, Pei Zhu, Jianhua Zhang, Xuyu Zhou, Feng Wang, Sheng Ye
Neoantigens derived from somatic mutations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), the most frequently mutated oncogene, represent promising targets for cancer immunotherapy. Recent research highlights the potential role of human leukocyte antigen (HLA) allele A*11:01 in presenting these altered KRAS variants to the immune system. In this study, we successfully generate and identify murine T-cell receptors (TCRs) that specifically recognize KRAS8-16 G12V from three predicted high affinity peptides...
April 29, 2024: Communications Biology
https://read.qxmd.com/read/38680862/identification-of-differentially-expressed-genes-and-splicing-events-in-early-onset-colorectal-cancer
#5
JOURNAL ARTICLE
Olivia M Marx, Marc M Mankarious, Walter A Koltun, Gregory S Yochum
BACKGROUND: The incidence of colorectal cancer (CRC) has been steadily increasing in younger individuals over the past several decades for reasons that are incompletely defined. Identifying differences in gene expression profiles, or transcriptomes, in early-onset colorectal cancer (EOCRC, < 50 years old) patients versus later-onset colorectal cancer (LOCRC, > 50 years old) patients is one approach to understanding molecular and genetic features that distinguish EOCRC. METHODS: We performed RNA-sequencing (RNA-seq) to characterize the transcriptomes of patient-matched tumors and adjacent, uninvolved (normal) colonic segments from EOCRC (n=21) and LOCRC (n=22) patients...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38680054/expanding-the-potential-of-neoantigen-vaccines-harnessing-bacille-calmette-gu%C3%A3-rin-cell-wall-based-nanoscale-adjuvants-for-enhanced-cancer-immunotherapy
#6
JOURNAL ARTICLE
Kangkang Liu, Jing Peng, Yunfei Guo, Yiming Li, Xiang Qi, Dengyi Duan, Taipeng Li, Jianmin Li, Yuanjie Niu, Gang Han, Yang Zhao
Personalized antitumor immunotherapy utilizing neoantigen vaccines holds great promise. However, the limited immunogenicity of existing recognized neoantigens and the inadequate stimulation of antitumor immune responses by conventional adjuvants pose significant challenges. To address these limitations, we developed a nanovaccine that combines a BCG bacterial cell wall skeleton (BCG-CWS) based nanoscale adjuvant (BCNA) with peptide neoantigens (M27 and M30). This integrated approach provides an efficient translational strategy for cancer immunotherapy...
April 29, 2024: ACS Nano
https://read.qxmd.com/read/38679698/immunosuppressive-tumor-microenvironment-and-immunotherapy-of-hepatocellular-carcinoma-current-status-and-prospectives
#7
REVIEW
Ke-Yu Shen, Ying Zhu, Sun-Zhe Xie, Lun-Xiu Qin
Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs have been the major trend in this area. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective treatment for advanced HCC. However, the majority of HCC patients obtain limited benefits...
April 29, 2024: Journal of Hematology & Oncology
https://read.qxmd.com/read/38677758/aldehyde-dehydrogenese-1-high-cancer-stem-like-cells-cancer-initiating-cells-escape-from-cytotoxic-t-lymphocytes-due-to-lower-expression-of-human-leukocyte-antigen-class-1
#8
JOURNAL ARTICLE
Tomohide Shirosaki, Noriko Kawai, Yuma Ebihara, Aiko Murai, Terufumi Kubo, Rena Morita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Toshiaki Shichinohe, Yoshihiko Hirohashi, Satoshi Hirano, Toshihiko Torigoe
BACKGROUND/AIM: Human gastric cancer stem-like cells (CSCs)/cancer-initiating cells can be identified as aldehyde dehydrogenase-high (ALDHhigh ) cells. Cancer immunotherapy employing immune checkpoint blockade has been approved for advanced gastric cancer cases. However, the effectiveness of cancer immunotherapy against gastric CSCs/CICs remains unclear. This study aimed to investigate the susceptibility of gastric CSCs/CICs to immunotherapy. MATERIALS AND METHODS: Gastric CSCs/CICs were isolated as ALDHhigh cells using the human gastric cancer cell line, MKN-45...
May 2024: Anticancer Research
https://read.qxmd.com/read/38675779/case-report-long-term-survival-of-a-patient-with-cerebral-metastasized-ovarian-carcinoma-treated-with-a-personalized-peptide-vaccine-and-anti-pd-1-therapy
#9
Henning Zelba, Christina Kyzirakos, Simone Kayser, Borong Shao, Annekathrin Reinhardt, Natalia Pieper, Armin Rabsteyn, Dennis Döcker, Sorin Armeanu-Ebinger, Matthias Kloor, Dirk Hadaschik, Martin Schulze, Florian Battke, Alexander Golf, Saskia Biskup
Ovarian cancer is one of the most common cancers among women and the most lethal malignancy of all gynecological cancers. Surgery is promising in the early stages; however, most patients are first diagnosed in the advanced stages, where treatment options are limited. Here, we present a 49-year-old patient who was first diagnosed with stage III ovarian cancer. After the tumor progressed several times under guideline therapies with no more treatment options available at that time, the patient received a fully individualized neoantigen-derived peptide vaccine in the setting of an individual healing attempt...
April 9, 2024: Vaccines
https://read.qxmd.com/read/38671743/autoepicollect-a-novel-machine-learning-based-gui-software-for-vaccine-design-application-to-pan-cancer-vaccine-design-targeting-pik3ca-neoantigens
#10
JOURNAL ARTICLE
Madhav Samudrala, Sindhusri Dhaveji, Kush Savsani, Sivanesan Dakshanamurthy
Previous epitope-based cancer vaccines have focused on analyzing a limited number of mutated epitopes and clinical variables preliminarily to experimental trials. As a result, relatively few positive clinical outcomes have been observed in epitope-based cancer vaccines. Further efforts are required to diversify the selection of mutated epitopes tailored to cancers with different genetic signatures. To address this, we developed the first version of AutoEpiCollect, a user-friendly GUI software, capable of generating safe and immunogenic epitopes from missense mutations in any oncogene of interest...
March 27, 2024: Bioengineering
https://read.qxmd.com/read/38671318/tlr3-activation-enhances-abscopal-effect-of-radiotherapy-in-hcc-by-promoting-tumor-ferroptosis
#11
JOURNAL ARTICLE
Liman Qiu, Hongbing Ji, Kai Wang, Wenhan Liu, Qizhen Huang, Xinting Pan, Honghao Ye, Zhenli Li, Geng Chen, Xiaohua Xing, Xiuqing Dong, Ruijing Tang, Haipo Xu, Jingfeng Liu, Zhixiong Cai, Xiaolong Liu
Radiotherapy (RT) has been reported to induce abscopal effect in advanced hepatocellular carcinoma (HCC), but such phenomenon was only observed in sporadic cases. Here, we demonstrated that subcutaneous administration of Toll-like receptor 3 (TLR3) agonist poly(I:C) could strengthen the abscopal effect during RT through activating tumor cell ferroptosis signals in bilateral HCC subcutaneous tumor mouse models, which could be significantly abolished by TLR3 knock-out or ferroptosis inhibitor ferrostatin-1. Moreover, poly(I:C) could promote the presentation of tumor neoantigens by dendritic cells to enhance the recruitment of activated CD8+ T cells into distant tumor tissues for inducing tumor cell ferroptosis during RT treatment...
April 26, 2024: EMBO Molecular Medicine
https://read.qxmd.com/read/38670854/revealing-the-nature-of-pt-based-immunotherapy-through-the-lens-of-neoantigens-in-cancer
#12
JOURNAL ARTICLE
Qi Xue, Wenhao Yu, Jie P Li, Chuan He, Zijian Guo
No abstract text is available yet for this article.
April 16, 2024: Science Bulletin
https://read.qxmd.com/read/38669788/the-tumor-immune-composition-of-mismatch-repair-deficient-and-epstein-barr-virus-positive-gastric-cancer-a-systematic-review
#13
REVIEW
J Bos, T S Groen-van Schooten, C P Brugman, F S Jamaludin, H W M van Laarhoven, S Derks
BACKGROUND: Gastric cancer (GC), known for its unfavorable prognosis, has been classified in four distinct molecular subtypes. These subtypes not only exhibit differences in their genome and transcriptome but also in the composition of their tumor immune microenvironment. The microsatellite instable (MSI) and Epstein-Barr virus (EBV) positive GC subtypes show clear clinical benefits from immune checkpoint blockade, likely due to a neoantigen-driven and virus-driven antitumor immune response and high expression of immune checkpoint molecule PD-L1...
April 20, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38669611/state-of-the-art-advancements-on-cancer-vaccines-and-biomarkers
#14
REVIEW
Scott Strum, Mads Hald Andersen, Inge Marie Svane, Lillian L Siu, Jeffrey S Weber
The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms. To date, these efforts have generally been met with minimal success. However, in the era of improved methods and technological advancements, supported by compelling preclinical and clinical data, a wave of renewed interest in the field offers the promise of discovering field-changing paradigms in the management of established and resected disease using cancer vaccines...
June 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38666722/high-throughput-quantitative-assessments-of-the-chemical-complementarity-of-celiac-disease-related-igh-cdr3s-and-a-gliadin-epitope
#15
JOURNAL ARTICLE
Rahul Jain, Max Bressler, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck
The long-term value of efficient antigen discovery includes gaining insights into the variety of potential cancer neoantigens, effective vaccines lacking adverse effects, and adaptive immune receptor (IR) targets for blocking adaptive IR-antigen interactions in autoimmunity. While the preceding goals have been partially addressed via big data approaches to HLA-epitope binding, there has been little such progress in the big data setting for adaptive IR-epitope binding. This delay in progress for the latter is likely due to, among other things, the much more complicated adaptive IR repertoire in an individual compared to individual HLA alleles...
April 26, 2024: International Immunology
https://read.qxmd.com/read/38665920/targeted-acidosis-mediated-delivery-of-antigenic-mhc-binding-peptides
#16
JOURNAL ARTICLE
Joey J Kelly, Emily T Ankrom, Sarah E Newkirk, Damien Thévenin, Marcos M Pires
Cytotoxic T lymphocytes are the primary effector immune cells responsible for protection against cancer, as they target peptide neoantigens presented through the major histocompatibility complex (MHC) on cancer cells, leading to cell death. Targeting peptide-MHC (pMHC) complex offers a promising strategy for immunotherapy due to their specificity and effectiveness against cancer. In this work, we exploit the acidic tumor micro-environment to selectively deliver antigenic peptides to cancer using pH(low) insertion peptides (pHLIP)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38663178/somatic-mutations-that-affect-early-genetic-progression-and-immune-microenvironment-in-gastric-carcinoma
#17
JOURNAL ARTICLE
Xiaoxiao Li, Zirui Tang, Zhaopeng Li, Zhao Li, Ping Zhao, Yi Song, Kexin Yang, Zihan Xia, Yinan Wang, Dong Guo
Gastric carcinoma (GC) is a high heterogeneity and malignant tumor with a poor prognosis. The current implementation of immunotherapy in GC is limited due to the insufficient exploration of immune-related mutations and speculated early mutation events. Therefore, we performed whole-exome sequencing on 40 patients with GC to explore their genetic characteristics, shedding light on the order of genetic events, somatic mutations impacting the immune microenvironment, and potential biomarkers for immunotherapy...
April 14, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38653798/discovery-of-tumor-reactive-t-cell-receptors-by-massively-parallel-library-synthesis-and-screening
#18
JOURNAL ARTICLE
Ziva Moravec, Yue Zhao, Rhianne Voogd, Danielle R Cook, Seon Kinrot, Benjamin Capra, Haiyan Yang, Brenda Raud, Jiayu Ou, Jiekun Xuan, Teng Wei, Lili Ren, Dandan Hu, Jun Wang, John B A G Haanen, Ton N Schumacher, Xi Chen, Ely Porter, Wouter Scheper
T cell receptor (TCR) gene therapy is a potent form of cellular immunotherapy in which patient T cells are genetically engineered to express TCRs with defined tumor reactivity. However, the isolation of therapeutic TCRs is complicated by both the general scarcity of tumor-specific T cells among patient T cell repertoires and the patient-specific nature of T cell epitopes expressed on tumors. Here we describe a high-throughput, personalized TCR discovery pipeline that enables the assembly of complex synthetic TCR libraries in a one-pot reaction, followed by pooled expression in reporter T cells and functional genetic screening against patient-derived tumor or antigen-presenting cells...
April 23, 2024: Nature Biotechnology
https://read.qxmd.com/read/38649621/merkel-cell-carcinoma-integrating-epidemiology-immunology-and-therapeutic-updates
#19
REVIEW
Jürgen C Becker, Andreas Stang, David Schrama, Selma Ugurel
Merkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. Its carcinogenesis is based either on the integration of the Merkel cell polyomavirus or on ultraviolet (UV) mutagenesis, both of which lead to high immunogenicity either through the expression of viral proteins or neoantigens. Despite this immunogenicity resulting from viral or UV-associated carcinogenesis, it exhibits highly aggressive behavior. However, owing to the rarity of MCC and the lack of epidemiologic registries with detailed clinical data, there is some uncertainty regarding the spontaneous course of the disease...
April 22, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38646651/programming-peptide-oligonucleotide-nano-assembly-for-engineering-of-neoantigen-vaccine-with-potent-immunogenicity
#20
JOURNAL ARTICLE
Zhichu Xiang, Jianhua Lu, Shangrui Rao, Chenxing Fu, Yuying Yao, Yongdong Yi, Yang Ming, Weijian Sun, Weisheng Guo, Xiaoyuan Chen
Background: Neoantigen nanovaccine has been recognized as a promising treatment modality for personalized cancer immunotherapy. However, most current nanovaccines are carrier-dependent and the manufacturing process is complicated, resulting in potential safety concerns and suboptimal codelivery of neoantigens and adjuvants to antigen-presenting cells (APCs). Methods: Here we report a facile and general methodology for nanoassembly of peptide and oligonucleotide by programming neoantigen peptide with a short cationic module at N-terminus to prepare nanovaccine...
2024: Theranostics
keyword
keyword
93159
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.